November 11 th at 8:30 AM ET Hosted a Virtual Acute Myeloid Leukemia KOL event with internationally renowned Acute Myeloid ...

Highlights,Hemogenyx Pharmaceuticals secures funding for phase I trials of its HEMO-CAR-T therapy.,The therapy focuses on ...

Investigators say adding RNA interference (RNAi) therapy to current treatment modalities may improve outcomes in patients with acute myeloid leukemia (AML) with internal tandem duplication in the ...

Mizuho Securities analyst Salim Syed has maintained their bullish stance on KURA stock, giving a Buy rating today. Salim Syed’s rating ...

About Hemogenyx Pharmaceuticals plc Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and ...

HemoGenyx Pharmaceuticals Plc (GB:HEMO) has released an update. Hemogenyx Pharmaceuticals has secured a £600,000 investment from an institutional ...

AML: Acute myeloid leukemia; CLL: C-type lectin-like molecule; CXCR: CXC chemokine receptor; N/A: Not applicable; NF: Nuclear factor. Acute myeloid leukemia (AML) remains incurable for the ...

Researchers with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and PrECOG, LLC, will present a variety of abstracts that aim to improve treatments for patients with lymphoma and acute leukemias at ...

Presentation at ASH will Feature Results from the Phase 2a Trial of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia After Venetoclax ...

Life was good for Betsy Ehrenberg. It was 2017, and she was 68, a partner at Boston law firm Pyle Rome Ehrenberg PC. She represented unions in collective bargaining matters and workers who’d ...

Cellectis has deprioritized one of its leukemia-focused candidates in order to focus on its other two clinical-stage CAR-T therapies. | Cellectis has deprioritized one of its leukemia-focused ...

In a recent publication of the acute myeloid leukemia (AML) arm of the Tumor Profiler, researchers demonstrated that multi-OMICS profiles can be generated in a clinically meaningful turnaround time ...